Cannabis for Hot Flashes
Popular among menopausal women, but no trials show it reduces hot flashes directly.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Hot flashes are driven by shifts in the brain's temperature control, not by something cannabis has been shown to fix. Women report cannabis helps them feel better during menopause, but that's mostly through sleep, anxiety relief, or just caring less — not through stopping the flashes themselves. If you're choosing cannabis over proven treatments like HRT or SSRIs specifically for hot flashes, you're gambling with an unknown. Used alongside standard care for sleep? That's a different conversation with your doctor.
Plain-language summary
Hot flashes and night sweats are the classic vasomotor symptoms of perimenopause and menopause. They're driven by changes in how the brain's thermoregulatory center responds to shifting estrogen levels, mediated in part by KNDy neurons in the hypothalamus [1].
Cannabis is popular among menopausal women. A 2020 survey of North American women found that over a quarter of respondents had used cannabis to manage menopause symptoms, and most said it helped [2]. A larger 2024 survey published in Menopause found similar patterns [3].
But popularity is not proof. There are no randomized controlled trials showing that THC, CBD, or whole-plant cannabis reduces hot flash frequency or severity No data. What cannabis may do is help you cope with hot flashes by improving sleep, reducing anxiety, or blunting the emotional weight of the experience — indirect effects, not a physiological fix to the underlying thermoregulatory disorder.
This is not medical advice. Talk to a clinician familiar with both menopause and cannabis before making decisions, especially if you have cardiovascular risk factors, a history of hormone-sensitive cancer, or take other medications.
What probably works for hot flashes
Nothing about cannabis has been shown to reduce hot flashes in controlled trials No data.
This is the key fact. There is no published randomized controlled trial — with THC, CBD, or a combination — demonstrating a reduction in the frequency, duration, or intensity of vasomotor symptoms. If a product page tells you otherwise, ask for the peer-reviewed citation.
In contrast, menopausal hormone therapy (MHT/HRT) reduces hot flash frequency by 75% or more in trials [4][5] Strong evidence. Fezolinetant (FDA-approved 2023), a neurokinin-3 receptor antagonist that targets the KNDy pathway, also shows strong efficacy [6] Strong evidence. SSRIs and SNRIs such as low-dose paroxetine and venlafaxine reduce hot flashes in controlled trials [7] Strong evidence. Gabapentin and oxybutynin have moderate evidence supporting their use [7] Strong evidence.
Cannabis has not been tested against any of these in head-to-head trials, and it has not been shown to work at all for the underlying vasomotor mechanism.
What might work (indirect effects)
Cannabis has better-supported effects on symptoms that co-occur with hot flashes. These indirect effects may be why some women report feeling better during menopause when they use cannabis:
Sleep disruption from night sweats. Low-to-moderate doses of THC can reduce sleep-onset latency in some people, though tolerance builds quickly and long-term regular use may worsen sleep architecture [8] Weak / limited. CBD's effects on sleep are mixed and highly dose-dependent [9] Weak / limited.
Anxiety and mood symptoms during menopause. CBD shows modest anxiolytic effects in some controlled studies, though rigorous studies specific to menopausal women are lacking [10] Weak / limited. Low-dose THC may reduce anxiety in certain contexts, but this effect is dose- and individual-dependent; higher doses often worsen anxiety Weak / limited.
Overall experience of menopause. The 2020 and 2024 survey studies suggest women find cannabis helpful for the broader menopause experience, which likely reflects these indirect coping effects rather than direct action on hot flashes themselves [2][3] Weak / limited.
Importantly: helping you cope is not the same as treating the condition. If reducing hot flashes is the goal, cannabis has no evidence. If managing sleep or anxiety around menopause is the goal, it has weak but real support — and other options (sleep hygiene, cognitive behavioral therapy, SSRIs) have stronger evidence.
What doesn't work or lacks evidence
CBD isolate for hot flash frequency or severity. No RCT evidence No data. Widely marketed for menopause; claims consistently outrun data.
Topical CBD for hot flashes. Biologically implausible for a centrally-mediated thermoregulatory symptom (the problem is in the brain, not the skin), and no clinical trials exist No data.
"Balancing hormones" with cannabis. A common marketing claim in menopause CBD products. Cannabinoids do interact with the endocrine system in complex ways [11], but there is no evidence they restore or rebalance estrogen levels in a way that treats menopause or vasomotor symptoms No data.
Specific strains or terpene profiles targeting menopause. No controlled evidence. Popular claims about "relaxing indicas" vs. "energizing sativas" do not reliably predict clinical effects, and strain names are notoriously unreliable Disputed. Strains sold for menopause are not different from marketing folklore.
What we don't know
Almost everything remains unclear. We don't know:
- Whether any cannabinoid, at any dose, affects the hypothalamic KNDy circuitry that generates hot flashes.
- Whether long-term cannabis use in perimenopause alters symptom trajectory (makes them better, worse, or unchanged over time).
- How cannabis interacts with hormone therapy (HRT) or with SSRIs/SNRIs prescribed for hot flashes.
- Whether there are cannabinoid–menopause interactions specific to bone density, cardiovascular risk, cognition, or depression during the menopausal transition.
- Whether cannabis is safe for women with a history of hormone-sensitive breast cancer, particularly given potential interactions with tamoxifen metabolism.
The research pipeline is thin. The 2023 position statement from the Menopause Society on nonhormone therapy for vasomotor symptoms did not recommend cannabis, citing insufficient evidence [7].
Risks and drug interactions
Cardiovascular effects. Menopause increases cardiovascular risk on its own. THC transiently raises heart rate and blood pressure; smoked cannabis carries additional acute cardiopulmonary risks [12] Strong evidence. If you have hypertension, arrhythmia, coronary disease, or other cardiovascular conditions, discuss cannabis with your clinician before use.
Drug interactions. CBD inhibits CYP3A4 and CYP2C19 and can significantly raise blood levels of many medications, including some SSRIs, benzodiazepines, and warfarin [13] Strong evidence. See Cannabis and Polypharmacy Risks for detailed guidance. THC and CBD can both interact with tamoxifen metabolism — relevant if you have a history of hormone-sensitive breast cancer [13] Weak / limited.
Bone health. Menopause accelerates bone loss. Chronic heavy cannabis use has been associated with lower bone mineral density in some studies, which could compound menopausal osteoporosis risk [14] Weak / limited.
Cognition and mood. Perimenopause already involves brain fog and mood shifts for many people. Regular THC use can worsen short-term memory and, in some users, anxiety or depression Strong evidence.
Cannabis use disorder. Cannabis dependence affects roughly 9–10% of adult users, with significantly higher rates for daily users Strong evidence. Risk is higher in women and in people who start use in midlife.
Smoking and respiratory health. If cannabis is smoked, it carries the same respiratory risks as tobacco smoke and may worsen existing asthma or COPD Strong evidence.
Comparing cannabis to standard treatments
For hot flashes specifically:
| Treatment | Evidence | Efficacy | Notes |
|---|---|---|---|
| Menopausal hormone therapy (MHT/HRT) | Strong RCT evidence | Reduces hot flashes 75%+ | First-line for women without contraindications; also addresses vaginal dryness, bone loss |
| Fezolinetant (Veozah) | Strong RCT evidence | ~60–70% reduction in moderate-to-severe flashes | FDA-approved 2023; targets KNDy pathway directly; newer, fewer long-term data |
| SSRIs/SNRIs (paroxetine, venlafaxine) | Strong RCT evidence | ~50–60% reduction | Well-established; also help mood; drug interactions possible |
| Gabapentin | Moderate RCT evidence | ~40–50% reduction | Non-hormonal, generally well-tolerated; can cause drowsiness |
| Cannabis (THC/CBD) | No RCT evidence | Unknown for hot flashes; may help sleep/anxiety indirectly | Widely marketed; claims outrun evidence; interactions with other meds; less predictable effects |
Someone choosing cannabis over evidence-based options specifically for hot flash reduction is trading a known effective treatment for an unknown one. Using cannabis alongside standard treatment for co-occurring sleep disruption or anxiety is a more defensible calculation — but requires coordination with your prescriber because of drug interactions and unknown cumulative effects.
Sources
- Peer-reviewed Rance NE, Dacks PA, Mittelman-Smith MA, et al. (2013). Modulation of body temperature and LH secretion by hypothalamic KNDy neurons: a novel hypothesis on the mechanism of hot flushes. Frontiers in Neuroendocrinology, 34(3), 211-227.
- Peer-reviewed Dahlgren MK, El-Abboud C, Lambros AM, et al. (2022). A survey of medical cannabis use during perimenopause and postmenopause. Menopause, 29(9), 1028-1036.
- Peer-reviewed Han L, Yang Y, Ma M, et al. (2024). Cannabis use among midlife women for menopause-related symptoms. Menopause.
- Peer-reviewed MacLennan AH, Broadbent JL, Lester S, Moore V (2004). Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews, (4), CD002978.
- Peer-reviewed The Menopause Society (2023). The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause, 30(6), 573-590.
- Peer-reviewed Lederman S, Ottery FD, Cano A, et al. (2023). Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet, 401(10382), 1091-1102.
- Peer-reviewed Babson KA, Sottile J, Morabito D (2017). Cannabis, cannabinoids, and sleep: a review of the literature. Current Psychiatry Reports, 19(4), 23.
- Peer-reviewed Kisiolek JN, Flores VA, Ramani A, et al. (2023). Eight weeks of daily cannabidiol supplementation improves sleep quality and immune cell cytotoxicity. Nutrients, 15(19), 4173.
- Peer-reviewed Bergamaschi MM, Queiroz RH, Chagas MH, et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology, 36(6), 1219-1226.
- Peer-reviewed Brents LK (2016). Marijuana, the endocannabinoid system and the female reproductive system. Yale Journal of Biology and Medicine, 89(2), 175-191.
- Peer-reviewed Page RL, Allen LA, Kloner RA, et al. (2020). Medical marijuana, recreational cannabis, and cardiovascular health: A scientific statement from the American Heart Association. Circulation, 142(10), e131-e152.
- Peer-reviewed Brown JD, Winterstein AG (2019). Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine, 8(7), 989.
- Peer-reviewed Sophocleous A, Robertson R, Ferreira NB, et al. (2017). Heavy cannabis use is associated with low bone mineral density and an increased risk of fractures. American Journal of Medicine, 130(2), 214-221.
- Peer-reviewed Hasin DS, Saha TD, Kerridge BT, et al. (2015). Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry, 72(12), 1235-1242.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis Use in Older Adults — What the evidence shows about cannabis benefits and risks for people over 65.
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...